CIA
SYRE icon

Cape Investment Advisory’s Spyre Therapeutics SYRE Stock Holding History

Cape Investment Advisory’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.87K Buy
+21
New +$2.02K ﹤0.01% 1259

Other funds holding SYRE

Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Cape Investment Advisory's SYRE Position: Q3 2026 in Review

Cape Investment Advisory opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 21 shares worth $1.87K. The stake represents ﹤0.01% of the portfolio and ranks #1259 among its holdings.

8 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Cape Investment Advisory held 21 shares of Spyre Therapeutics worth $1.87K as of Q3 2026.
  • Spyre Therapeutics was a new Cape Investment Advisory position in Q3 2026.
  • Spyre Therapeutics made up ﹤0.01% of Cape Investment Advisory's portfolio in Q3 2026, its #1259 holding.
  • 8 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Cape Investment Advisory's 13F filing for Q3 2026, filed 13 Oct 2026.